Human cytomegalovirus (HCMV), a betaherpesvirus, is pathogenic almost exclusively in immunocompromised individuals. Cellular immune response is thought to control HCMV in immunocompetent people, both in the acute phase and in the latent infection which ensues (for a review, see reference 6). Cytotoxic CD8 ϩ T cells contribute greatly to immunological control, as revealed by the presence of cytotoxic CD8 ϩ T cells in patients who recover from acute infections (37) and by the prevention of HCMV disease following the injection of viral matrix-specific CD8 ϩ clones to bone marrow transplant patients (44) . CD4 ϩ T cells against HCMV proteins have also been described (4, 12, 28) , and a significant response towards IE1, the major immediate-early DNA-binding protein, has been reported (3, 9) . The precursor frequencies of IE1-specific CD4 ϩ T cells are high in latently infected individuals (9) , and cytokines such as gamma interferon (IFN-␥) and tumor necrosis factor alpha (TNF-␣) found in the supernatant of CD4 ϩ T-cell clones specific for IE1 significantly reduce HCMV replication (10) . The role of CD4 ϩ T cells in HCMV infections was inferred from these in vitro studies and from in vivo studies showing that CD4 ϩ T cells are required for the clearance of mouse cytomegalovirus (MCMV) in salivary glands of mice (22) .
Major histocompatibility complex (MHC) class II expression is a key element in the control of the immune response. It is required for the activation of T lymphocytes in the process of antigen (Ag) presentation by professional or nonprofessional antigen-presenting cells (APC) (13) . Three essential transactivators of MHC class II genes have been identified: RFX5 and RFX-AP are part of the RFX complex that binds to the X box of all MHC class II promoters, while the class II transactivator (CIITA) is itself tightly regulated, and this transactivator functions as the master controller of MHC class II expression, probably in all physiological conditions (30, 42) .
Both constitutive and inducible expressions of MHC class II genes are indeed dependent on CIITA, and the CIITA gene is itself controlled by distinct alternative promoters (33) . While CIITA promoters I and III are specific for constitutive expression in dendritic cells and B lymphocytes, respectively, induction of CIITA, and hence of MHC class II, by IFN-␥ is mediated by promoter IV. Activation by IFN-␥ takes place via a cascade of events which involves tyrosine phosphorylation of STAT1 by JAK1 and JAK2 kinases, followed by nuclear translocation and binding of STAT1 to a GAS sequence within the promoter of the target gene (reviewed in reference 8). In the case of the activation of CIITA promoter IV by IFN-␥, cooperation between three distinct and essential transacting factors, STAT1 and USF-1 (binding cooperatively to a GAS-E box motif) and IRF-1, has recently been described in detail (34) . This also explains why JAK1 and STAT1 mutants lack inducibility of MHC class II by IFN-␥ (31). The detailed dissection of these multiple steps of the cascade, from IFN-␥ activation to expression of MHC class II molecules (33, 34) , now allows the assignment of various types of inhibition to specific steps within this cascade.
APC capacity is triggered by IFN-␥ treatment in many cell types, due to the induction of expression of HLA class II, the invariant chain, and HLA-DM which catalyzes the release of invariant chain-derived Clip peptide from HLA class II molecules and allows the binding of processed peptides (36) . MHC class II molecules are known to present peptides derived from extracellular, exogenous Ag to CD4 ϩ T cells (36) . However, it appears that presentation of intracellular endogenous, especially viral, Ags is common (14, 23) . This suggests cognate interaction between CD4 ϩ T cell and the infected MHC class II-positive APC.
Immunological controls of cytomegaloviruses are counter-balanced by escape mechanisms from class I-mediated recognition by CD8 ϩ T cells, as recently described (46) . Several genes localized in the unique short (US) region of the HCMV genome are responsible for down regulating HLA class I expression at multiple levels through retrotranslocation of HLA class I heavy chain to the cytosol (US2 [19, 47] and US11 [21, 45] ), retention in the endoplasmic reticulum (US3 [1, 20] ) and inhibition of TAP translocation of peptides (US6 [2, 17, 26] ). The CD4 ϩ compartment of cellular immunity has been suspected to be down regulated since the observation by Sedmak et al. (38) that HCMV inhibits HLA class II expression induced by IFN-␥. A recent report by Miller et al. (32) has described a mechanism of JAK1 proteolysis by HCMV to explain the inhibition of IFN-␥-mediated induction of HLA class II. In mice, Heise et al. (15) have reported that MCMV down regulates IFN-␥-induced expression of MHC class II-related molecules through the inhibition of their transcription. The mechanism, which occurs downstream of STAT1 activation, has yet to be determined.
In this paper, we made use of an astrocytoma cell line, U373 MG, which is fully permissive to HCMV. This cell line can also be induced to express HLA-DR by treatment with IFN-␥ and to subsequently present Ag to HCMV IE1-specific CD4 ϩ T cells (11) . We show here that HCMV infection prevents induction of HLA-DR expression by IFN-␥ in U373 MG cells. This inhibition occurs downstream of the activation of STAT1, whose phosphorylation and nuclear translocation are not inhibited by HCMV. CIITA transcription is strongly repressed by cotreatment of cells with IFN-␥ plus HCMV. Logically, this strong reduction of MHC class II expression by HCMV results in the absence of IE1 presentation and recognition by CD4 
MATERIALS AND METHODS

Virus, cell lines, and the IE1-specific CD4
؉ T-cell clone. HCMV (Towne strain) stocks were obtained by infection of foreskin fibroblasts at a multiplicity of infection (MOI) of 0.01 in 10% fetal calf serum (FCS) culture medium (RPMI-Glutamax I supplemented with sodium pyruvate and antibiotics from GIBCO-BRL). U373 MG cells were cultured in 10% FCS culture medium. HCMV, fibroblasts, and U373 MG cells were kind gifts from S. Michelson (Institut Pasteur, Paris, France).
Transfection of U373 MG cells with the pSR␣-neo/CIITA-Tag plasmid was performed by using the calcium phosphate method. Transfected cells were then cloned by limiting dilution and HLA-DR expression was controlled by flow cytometry.
The previously described CD4 ϩ T-cell clone FzD3 specific for IE1 was obtained by limiting dilution from a healthy HCMV-seropositive donor (10) . FzD3 clone was maintained by weekly restimulations with phytohemagglutinin and allogeneic irradiated peripheral blood mononuclear cells in the presence of interleukin 2 (IL-2) (20 U/ml) in culture medium supplemented with 10% human serum.
HCMV inoculum was inactivated by using alternating UV and gamma irradiation. Both were used to ensure that the results did not depend on the inactivation method.
MAb. E13, an immunoglobulin G1 (IgG1) mouse monoclonal antibody (MAb) specific for immediate-early proteins UL122 to -123, was a kind gift from M.-C. Mazeron (Hôpital Lariboisière, Paris, France). MAb CCH2 (anti-UL44 early protein) was purchased from DAKO. Control IgG1 myeloma protein was from Sigma. W6/32, OKT3, and L243 MAbs were purchased from the American Type Culture Collection. DA6-231, an anti-HLA-DR ␤ chain (43) , was a kind gift from S. Demotz (University of Lausanne, Lausanne, Switzerland).
RNase protection assays. Quantitative analysis of CIITA and GBP mRNAs was performed by RNase protection assays as described in detail elsewhere (30) .
Immunoprecipitation. U373 MG (10 6 cells) was plated in culture medium in 25-cm 2 flasks and was either left untreated or was treated with IFN-␥ (300 U/ml), with IFN-␥ (300 U/ml) plus HCMV (MOI ϭ 5), or incubated with HCMV alone (MOI ϭ 5).
For MHC class I immunoprecipitation, cells were washed in phosphate-buffered saline (PBS) 24 h later, incubated in methionine-and-cysteine-free medium (Gibco) for 1 h, and labelled with [
35 S]methionine plus [ 35 S]cysteine (100 Ci/ ml) (ICN) for 2 h. Cells were lysed in lysis buffer (1% Nonidet P-40, 5 mM EDTA, 150 mM NaCl, 1 mM MgCl 2 , 0.05 mM phenylmethylsulfonyl fluoride [PMSF], 50 mM Tris [pH 7.6]) for 45 min on ice. Preclearing of the lysate was performed overnight by using protein A-conjugated Sepharose beads (Pharmacia). W6/32 antibody was then added to the lysate for 1.5 h at 4°C. Protein A-coupled Sepharose beads were then added, and incubation was continued for an additional 2 h at 4°C.
For MHC class II immunoprecipitation, cells were washed in PBS 18 h after treatment, incubated for 1 h in methionine-and-cysteine-free medium and labelled with [ 35 S]methionine plus [ 35 S]cysteine for the last 6 h. Cells were lysed in lysis buffer (1% Nonidet P-40, 5 mM EDTA, 150 mM NaCl, 1 mM MgCl 2 , 0.05 mM PMSF, 50 mM Tris [pH 7.6]) for 45 min on ice. Preclearings were performed as follows: the cell lysates were incubated with normal mouse serum and protein G-conjugated Sepharose beads for 2 h. A second preclearing was performed by using 50 l of zysorbin (Zymed) for 4 h. DA6-231 antibody was then added to the cell lysates, and incubation was performed overnight at 4°C. Protein G-conjugated Sepharose beads were then added, and incubation was maintained for another 2 h. For both MHC class I and class II immunoprecipitations, the beads were then washed and boiled in 5% ␤-mercaptoethanol reducing Laemmli buffer and run on 10% polyacrylamide gels. Gels were fixed, incubated in Amplify (Amersham), vacuum dried, and exposed to hyperfilm-MP (Amersham).
Flow cytometry. U373 MG cells were infected by using supernatant from infected fibroblasts. U373 MG cells were treated with IFN-␥ (300 U/ml) or with IFN-␥ plus HCMV or IFN-␥ plus gamma-irradiated HCMV. The contents of wells were aspirated and replaced with fresh medium and fresh IFN-␥ on day 3. The culture was allowed to proceed for an additional 3 days. U373 MG cells were then double stained for cell surface HLA-DR and intracellular immediate-early (UL122 to -123) or early (UL44) proteins and analyzed by flow cytometry. Cell viability was assessed by using Trypan Blue exclusion and was found to be greater than 80%.
For double staining, U373 MG cells were incubated for 20 min at 4°C with saturating amounts of OKT3 (used as a control) or L243 MAb in Ca 2ϩ /Mg 2ϩ -free PBS-3% FCS plus 0.1% NaN 3 (staining buffer), washed twice in staining buffer, then incubated with goat F(abЈ) 2 fragment anti-mouse IgG coupled to fluorescein isothiocyanate (Sigma). Cells were washed twice in staining buffer, then incubated for 90 min at 4°C with OKT3 to saturate unbound anti-mouse IgG-fluorescein isothiocyanate Fab sites, then fixed with 1% paraformaldehyde for 20 min at 4°C and washed with PSN buffer (PBS ϩ 1% normal goat serum ϩ 1 mM EDTA ϩ 0.05% saponin). MAbs (IgG1) specific for HCMV immediateearly (E13) and early (CCH2) proteins, or IgG1 myeloma protein (Sigma) used as a control, were diluted in PSN, and added to cell samples for a 90-min incubation at 37°C. Cells were washed twice in PSN buffer and incubated for 20 min at 4°C with isotype-specific phycoerythrin-coupled anti-IgG1 goat antimouse F(abЈ) 2 antiserum (Southern Biotechnology). Samples were then analyzed by using an EPICS Elite cell sorter.
Immunocytochemistry. U373 MG cells were seeded at 30,000 cells per well (24-well plate; FALCON) in RPMI 1640 supplemented with heat-inactivated 10% FCS and were cultured for 24 h. They were then cultured in serum-free medium for another 24 h. Then they were treated with IFN-␥ (300 U/ml) and, except for controls, were infected with HCMV for 15 or 30 min or 1, 6, or 24 h.
Cells were washed once with 1ϫ PBS and were fixed with 1 ml of 1ϫ PBS containing 3% paraformaldehyde for 10 min at 4°C. Immunochemistry was then performed by using a rabbit PhosphoPlus STAT1 (Tyr 701) antiserum (Biolabs). The biotinylated secondary antibody was a peroxidase-coupled horse anti-mouse and anti-rabbit IgG (Vectastain ABC kit; Vector Laboratories). Staining was revealed by using diaminobenzidine (Sigma) and H 2 O 2 .
IE1-specific CD4 ؉ T-cell clone response. U373 MG cells were seeded at 1.5 ϫ 10 5 cells/well in RPMI 1640 supplemented with 10% FCS in a 6-well plate (FALCON). Cells were mock infected or treated with HCMV or UV-irradiated HCMV (MOI ϭ 5) and treated simultaneously with IFN-␥ (300 U/ml). Cells were fed on day 3 with fresh medium supplemented with IFN-␥ (300 U/ml) and were left in culture for an additional 2 days.
U373 MG-CIITA cells were mock infected or infected with either HCMV or UV-irradiated HCMV at an MOI of 5 for 5 days. U373 MG and U373 MG-CIITA cells were incubated with specific IE1 peptide (amino acids 91 to 110) (Neosystem, Strasbourg, France) at a concentration of 10 M overnight.
U373 MG and U373 MG-CIITA cells were then harvested, washed, and plated in triplicate (3 ϫ 10 4 cells per well) in a 96-well plate in the presence of 3 ϫ 10 U/ml) plus HCMV (MOI ϭ 5) for different time points in 10% FCS culture medium.
In another protocol derived from reference 32, cells were left untreated, treated with IFN-␥ alone, or treated with IFN-␥ after 72 h of infection by HCMV.
The incubation was stopped by using ice-cold PBS. Cells were washed, detached with a cell scraper in PBS, and pelleted at 300 ϫ g for 10 min. Cells were lysed in reducing Laemmli buffer. Samples equivalent to 3 ϫ 10 5 cells each were run on a 7.5% acrylamide gel and transferred to nitrocellulose membranes (Amersham). Membranes were incubated with a rabbit PhosphoPlus STAT1 (Tyr 701)-specific antiserum (Biolabs), followed by incubation with a secondary peroxidase-coupled anti-rabbit antiserum (Biolabs). Bands were revealed by using an ECL detection kit (Amersham).
RESULTS
Inhibition of IFN-␥-induced HLA-DR expression by HCMV infection.
We tested the induction of HLA-DR by IFN-␥ in infected U373 MG cells (Fig. 1) . As expected and as previously shown (11), IFN-␥ in the absence of HCMV induced high levels of HLA-DR expression in U373 MG cells. Simultaneous coincubation of HCMV with IFN-␥ almost totally prevented HLA-DR expression. A small proportion (12%) of cells expressed low levels of HLA-DR molecules in spite of HCMV infection. This incomplete down regulation of HLA-DR by HCMV was observed in all the experiments performed. In these samples, immediate-early (UL122 and UL123) and early (UL44) proteins were detectable by using E13 and CCH2 MAbs, respectively. This indicated that, when U373 MG cells are incubated with IFN-␥ and HCMV simultaneously, IFN-␥ does not prevent HCMV infection, but HCMV inhibits IFN-␥-induced HLA-DR expression. To test whether active infection accounted for the inhibition of HLA-DR, HCMV was gamma irradiated (800 Gy) and tested in the same experiment. Twenty percent of the cells expressed residual immediate-early proteins, and only 8% expressed the protein encoded by UL44, recognized by CCH2 antibody. This clearly showed that the virus was inactivated. Irradiated HCMV inoculum did not prevent IFN-␥-induced HLA-DR expression. In addition, pelleted HCMV, but neither supernatant nor UV-irradiated HCMV, repressed HLA-DR induction (results not shown). This suggested that neither virion-associated proteins nor cytokines included in the inoculum were responsible for repression of HLA-DR induction.
Inhibition of IFN-␥-induced HLA-DR synthesis by HCMV infection. To test whether the inhibition of HLA-DR expression was observed at an earlier step than cell surface expression, we immunoprecipitated nascent HLA-DR molecules from [
35 S]Met-[ 35 S]Cys-labelled U373 MG cells by using the ␤-chain-specific MAb DA6-231. As shown in Fig. 2 , a 24-h treatment with IFN-␥ induced the appearance of bands which correspond to the HLA-DR ␣, the invariant, and the HLA-DR ␤ chains, respectively. The ␤ chain, which contains fewer Met and Cys residues than the ␣ and invariant chains, was less labelled, and the corresponding band was fainter. In IFN-␥ plus HCMV-infected cells, these bands were no longer detected. This result confirms HCMV inhibition of HLA-DR expression in U373 MG cells and shows that this inhibition is detectable at the level of protein synthesis after a 24-h cotreatment with IFN-␥ plus HCMV.
MHC class I up regulation by IFN-␥ is not repressed by HCMV. To test whether HCMV also inhibited IFN-␥-induced
MHC class I upregulation, we performed immunoprecipitations of HLA-A, -B, and -C molecules by using W6/32 MAb. As shown in Fig. 3 , and as expected, MHC class I protein expression was upregulated by IFN-␥. This up regulation was not inhibited by HCMV concomitant infection. As previously described (19) (see Fig. 2 ). These results suggested that inhibition of HLA-DR expression was not related to defects in STAT1 phosphorylation in our experimental conditions. However, STAT1 phosphorylation was inhibited after a 72-h coincubation with IFN-␥ plus HCMV. Similar results were observed when we used foreskin fibroblasts (data not shown). Recently, Miller et al. (32) have described an inhibition of IFN-␥-induced HLA-DR expression by HCMV in endothelial cells and fibroblasts through JAK1 proteolysis, which logically leads to reduced STAT1 phosphorylation. These observations were made by using a different protocol, consisting of a 72-h preincubation with HCMV before IFN-␥ treatment. Using their protocol, we also observed that STAT1 phosphorylation was inhibited after 15 min and 6 h of IFN-␥ treatment in U373 MG-infected cells (Fig. 4B) . This shows that U373 MG cells were not refractory to the mechanism described by Miller et al., and our data suggest the existence of another mechanism, perhaps earlier in the infection, which does not involve the inhibition of STAT1 phosphorylation.
STAT1 is quickly translocated to the nucleus after phosphorylation (8) . In U373 MG cells, nuclear translocation of STAT1 occurred after 15 min of incubation with IFN-␥ (not shown). Figure 5 shows that IFN-␥-induced P-STAT1 translocation to the nucleus was not inhibited by HCMV infection even after a 24-h coincubation. Therefore, STAT1 activation and nuclear translocation occur with the same intensity and same kinetics in IFN-␥-and IFN-␥ plus HCMV-treated U373 MG cells at experimental time points when HCMV inhibits IFN-␥-induced HLA-DR expression.
Repression of CIITA mRNA expression by HCMV infection. Since HLA-DR repression was not mediated by a defect in STAT1 phosphorylation and nuclear translocation, we looked for an inhibition further down the pathway of IFN-␥ signalling. We therefore looked at CIITA transcription in IFN-␥-and IFN-␥ plus HCMV-treated U373 MG cells. RNase protection assays (Fig. 6) showed that CIITA mRNA expression was induced after 6 h of treatment with IFN-␥, as previously described (7, 41) . The levels of CIITA mRNA were 13.5 times lower in cells treated with IFN-␥ plus HCMV than in cells treated with IFN-␥ alone. Interestingly, expression of the GBP gene, which is also up-regulated by IFN-␥, was also inhibited by HCMV (ninefold decrease), implying a mechanism common to the regulation of these two genes. The kinetics of induction of CIITA by IFN-␥ and its inhibition in HCMVinfected cells suggest that the quick repression of CIITA after infection accounts for the observed reduction in HLA-DR expression by HCMV. In an additional experiment, CIITA transcription was found to be still repressed after 24 h of treatment with IFN-␥ plus HCMV (data not shown).
Restoration of CD4 ؉ T-cell clone recognition of HCMV IE1 by constitutive CIITA expression in infected U373 MG cells. We next tested the consequences of HLA-DR repression on the activation of a specific anti-IE1 T-cell clone which recognizes the HCMV IE1 peptide (amino acids 91 to 110) presented by HLA-DR3-typed U373 MG (11) . Figure 7 shows IFN-␥ production as an assay for activation of T-cell clone FzD11. This clone produced high amounts of IFN-␥ when incubated with IFN-␥-treated U373 MG cells pulsed with the IE1 peptide (amino acids 91 to 110) (Fig. 7A) . However, the FzD11 CD4 ϩ T-cell clone was not activated by U373 MG cells infected by HCMV and treated with IFN-␥ for 5 days. This was not due to the inhibition of IE1 production since high levels of immediate-early proteins were detectable in this protocol (Fig.  1) . Figure 7B shows that the FzD11 clone was activated in the presence of CIITA-transfected U373 MG cells (U373 MG- , and 72 h. STAT1 phosphorylation was evaluated in a Western blot by using an anti-P-Tyr-STAT1 specific antiserum. Levels of STAT1 protein were evaluated in the same samples by using an anti-STAT1 antiserum. (B) U373 MG cells were either incubated with IFN-␥ for 15 min or 6 h in the absence of HCMV or incubated with IFN-␥ after 72 h of infection with HCMV. STAT1 phosphorylation was then evaluated in a Western blot by using an anti-P-Tyr-STAT1 specific antiserum. Levels of STAT1 protein were evaluated in the same samples by using an anti-STAT1 antiserum. Three experiments, which gave similar results, were performed. the need for infectious virus to inhibit HLA-DR induction and from the observation of viral protein expression in cells with repressed HLA-DR. The inhibition of HLA-DR is not due to cytokines contained in the viral inoculum for the following reasons: first, irradiated virus had no negative effect on IFN-␥-induced HLA-DR expression; second, pelleted infectious virus prevented HLA-DR induction effectively (data not shown); third, the amounts of transforming growth factor ␤1, which is known to be involved in HLA-DR down regulation through inhibition of CIITA transcription (25, 35) , were found to be similar in the inoculum to that of regular 10% FCS culture medium (300 pg/ml) (data not shown), and IFN-␤ has been reported to act downstream of CIITA (29) . Treatment of cells with phosphonacetic acid did not prevent HLA-DR inhibition (data not shown), which suggests that the viral protein involved is encoded in the immediate-early and early phases of infection. Besides, the kinetics of CIITA inhibition (6 h postinfection) suggest that the repression occurs in the immediate-early phase of infection. However, this point needs further investigation to help identify the viral protein(s) involved.
Our present data point to a transcriptional modulation of CIITA expression due to viral infection. Therefore, inhibition of the IFN-␥-inducible promoter IV is expected to account for the down regulation of CIITA. This inhibition is not unique to CIITA, since repression of both CIITA and GBP was observed. As both are under the control of IRF-1 (5, 34), which is itself activated by STAT1 (27) , a defect in IRF-1 transcription or in its binding to the IRF-1 box of promoter IV may be suspected. However, the increase of HLA class I synthesis induced by IFN-␥, also under the control of IRF-1 (18), was not inhibited by HCMV, in accordance with a previous report (16) . This indicates uncoupling of HLA class I and class II regulation in response to IFN-␥ and HCMV and argues against a major role of IRF-1 in the inhibition of HLA-DR induction. Alternatively, functional activity of STAT1 through interaction with other transcriptional factors such as USF1 (34) may be impaired and result in down regulation of CIITA transcription.
Multistep inhibitions of IFN-␥-induced HLA class II expression and escape from CD4 ϩ T-cell response in HCMV infection are likely to represent the counterpart of HLA class I inhibition of expression (46) . A recent paper by Miller et al. (32) showed that degradation of the JAK1 protein was responsible for down regulation of HLA-DR in endothelial cells. Although this process was found to occur in the immediateearly or early phase of infection, it required infection of the cells prior to IFN-␥ treatment to effectively inhibit HLA-DR induction. In the present paper, it is clear that the impaired HLA-DR production was not due to a defect in STAT1 activation. Therefore, our protocol of simultaneous coincubation of IFN-␥ and HCMV unravels a new mechanism of HLA-DR inhibition which is not related to STAT1 activation, since STAT1 phosphorylation and nuclear translocation were present at a time point (24 h) when HLA-DR protein synthesis was repressed. Rather, this mechanism involves the inhibition of CIITA RNA expression. However, U373 MG was not refractory to the mechanism described by Miller et al., since we observed an inhibition of STAT1 phosphorylation when their protocol was applied (Fig. 4B) , and when we used our protocol, STAT1 phosphorylation was strongly diminished after 72 h of cotreatment with IFN-␥ plus HCMV. We conclude that several mechanisms can account for the diminished HLA-DR expression in response to IFN-␥. We suggest that CIITA repression occurs prior to inhibition of STAT1 phosphorylation. Another recent report showed inhibition of transcription of MHC class II by MCMV with normal STAT1 activation (15) similar to what we observed in HCMV. Whether the mechanism used by MCMV is similar to the one we describe in the present report remains to be investigated.
Our present data, which identify the defect in CIITA gene activation, also suggest that transcription of other genes which follow similar regulation, as shown for GBP, may be altered by HCMV infection. However, not all IFN-␥-inducible genes are expected to be the target of HCMV in view of normal up regulation of HLA class I synthesis in the presence of IFN-␥ and HCMV. The mechanism involved in HLA-DR down regulation, which occurs upstream of CIITA and downstream of STAT1 activation, suggests transcription regulation by an immediate-early protein. Current studies in our laboratory are aimed at identifying this viral protein(s). In addition to helping to understand HLA class II transcription and HCMV regulation of transcription, the identification of such a protein would be useful in situations where targeted immunosuppression is required to down modulate exacerbated (autoimmunity) or nonappropriate (transplantation) MHC class II expression.
Although U373 MG cells are not bona fide APC, they are capable of processing and presenting endogenous (40) . However, CD4
ϩ T-cell clones produce cytokines other than IFN-␥ and TNF-␣ which possess anti-HCMV activity and may reduce infection (10) . Our data suggest that HCMV allows infected cells to escape from CD4 ϩ recognition by blocking the required induction of HLA-DR.
In conclusion, we have shown, using U373 MG cells as a model, that HCMV escapes from anti-IE1 CD4 ϩ T-lymphocyte response in vitro by interfering with the IFN-␥-mediated induction of HLA-DR at the level of CIITA induction. HCMV has evolved a number of stealth mechanisms which may account for a very high prevalence of HCMV infection in the population and latency in immunocompetent hosts. The modulation of the anti-IE1 CD4 ϩ T-cell response is likely to play an important role in the host-HCMV balance. Further experiments are needed to demonstrate that the defect we describe here alters the functional CD4 ϩ T-cell response in acute infections in vivo.
